Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease

Author(s): Xiao-Zhong Jing, Hui-Jia Yang, Reyisha Taximaimaiti and Xiao-Ping Wang*

Volume 21, Issue 5, 2023

Published on: 14 November, 2022

Page: [1224 - 1240] Pages: 17

DOI: 10.2174/1570159X20666220915091022

Price: $65

conference banner
Abstract

Dopamine (DA) agonists, as an excellent dopamine replacement therapy for patients with early and advanced Parkinson's disease (PD), play a vital role in controlling motor and several nonmotor symptoms. Besides, the application of DA agonists may delay levodopa therapy and the associated risk of motor complications. Indeed, each DA agonist has unique pharmacokinetic and pharmacodynamic characteristics and therefore has different therapeutic efficacy and safety profile. The comorbidities, significant non-motor manifestations, concomitant medications, and clinical features of PD individuals should guide the selection of a specific DA agonist to provide a more patient-tailored treatment option. Thorough knowledge of DA agonists helps clinicians better balance clinical efficacy and side effects. Therefore, this review refers to recent English-written articles on DA agonist therapy for PD patients and summarizes the latest findings on non-ergot DA agonists as well as the advantages and disadvantages of each compound to help clinicians in the selection of a specific DA agonist. In addition, novel D1/D5 partial agonists and new formulations of DA agonists are also discussed

Keywords: Parkinson's disease, Dopamine (DA) agonists, Treatment, Motor Symptoms, Non-motor Symptoms, Advances

« Previous Next »
Graphical Abstract

[1]
Ascherio, A.; Schwarzschild, M.A. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol., 2016, 15(12), 1257-1272.
[http://dx.doi.org/10.1016/S1474-4422(16)30230-7] [PMID: 27751556]
[2]
Poewe, W.; Seppi, K.; Tanner, C.M.; Halliday, G.M.; Brundin, P.; Volkmann, J.; Schrag, A.E.; Lang, A.E. Parkinson disease. Nat. Rev. Dis. Primers, 2017, 3(1), 17013.
[http://dx.doi.org/10.1038/nrdp.2017.13] [PMID: 28332488]
[3]
Armstrong, M.J.; Okun, M.S. Diagnosis and Treatment of Parkinson Disease. JAMA, 2020, 323(6), 548-560.
[http://dx.doi.org/10.1001/jama.2019.22360] [PMID: 32044947]
[4]
Kalia, L.V.; Lang, A.E. Parkinson’s disease. Lancet, 2015, 386(9996), 896-912.
[http://dx.doi.org/10.1016/S0140-6736(14)61393-3] [PMID: 25904081]
[5]
Schapira, A.H.V. Etiology of Parkinson’s disease. Neurology, 2006, 66(10, Supplement 4)(Suppl. 4), S10-S23.
[http://dx.doi.org/10.1212/WNL.66.10_suppl_4.S10] [PMID: 16717248]
[6]
Olanow, C.W.; Agid, Y.; Mizuno, Y.; Albanese, A.; Bonucelli, U.; Damier, P.; De Yebenes, J.; Gershanik, O.; Guttman, M.; Grandas, F.; Hallett, M.; Hornykiewicz, O.; Jenner, P.; Katzenschlager, R.; Langston, W.J.; LeWitt, P.; Melamed, E.; Mena, M.A.; Michel, P.P.; Mytilineou, C.; Obeso, J.A.; Poewe, W.; Quinn, N.; Raisman-Vozari, R.; Rajput, A.H.; Rascol, O.; Sampaio, C.; Stocchi, F. Levodopa in the treatment of Parkinson’s disease: Current controversies. Mov. Disord., 2004, 19(9), 997-1005.
[http://dx.doi.org/10.1002/mds.20243] [PMID: 15372588]
[7]
Fox, S.H.; Katzenschlager, R.; Lim, S.Y.; Barton, B.; de Bie, R.M.A.; Seppi, K.; Coelho, M.; Sampaio, C. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov. Disord., 2018, 33(8), 1248-1266.
[http://dx.doi.org/10.1002/mds.27372] [PMID: 29570866]
[8]
Kulisevsky, J.; Oliveira, L.; Fox, S.H. Update in therapeutic strategies for Parkinson’s disease. Curr. Opin. Neurol., 2018, 31(4), 439-447.
[http://dx.doi.org/10.1097/WCO.0000000000000579] [PMID: 29746402]
[9]
Rascol, O.; Brooks, D.J.; Korczyn, A.D.; De Deyn, P.P.; Clarke, C.E.; Lang, A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N. Engl. J. Med., 2000, 342(20), 1484-1491.
[http://dx.doi.org/10.1056/NEJM200005183422004] [PMID: 10816186]
[10]
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA, 2000, 284(15), 1931-1938.
[http://dx.doi.org/10.1001/jama.284.15.1931] [PMID: 11035889]
[11]
Whone, A.L.; Watts, R.L.; Stoessl, A.J.; Davis, M.; Reske, S.; Nahmias, C.; Lang, A.E.; Rascol, O.; Ribeiro, M.J.; Remy, P.; Poewe, W.H.; Hauser, R.A.; Brooks, D.J. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol., 2003, 54(1), 93-101.
[http://dx.doi.org/10.1002/ana.10609] [PMID: 12838524]
[12]
Nutt, J.G.; Obeso, J.A.; Stocchi, F. Continuous dopamine-receptor stimulation in advanced Parkinson’s disease. Trends Neurosci., 2000, 23(10)(Suppl.), S109-S115.
[http://dx.doi.org/10.1016/S1471-1931(00)00029-X] [PMID: 11052228]
[13]
Beaulieu, J.M.; Gainetdinov, R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev., 2011, 63(1), 182-217.
[http://dx.doi.org/10.1124/pr.110.002642] [PMID: 21303898]
[14]
Beaulieu, J.M.; Espinoza, S.; Gainetdinov, R.R. Dopamine receptors - IUPHAR Review 13. Br. J. Pharmacol., 2015, 172(1), 1-23.
[http://dx.doi.org/10.1111/bph.12906] [PMID: 25671228]
[15]
Kvernmo, T.; Härtter, S.; Burger, E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin. Ther., 2006, 28(8), 1065-1078.
[http://dx.doi.org/10.1016/j.clinthera.2006.08.004] [PMID: 16982285]
[16]
Jenner, P. Pharmacology of dopamine agonists in the treatment of Parkinson’s disease. Neurology, 2002, 58(4)(Suppl. 1), S1-S8.
[http://dx.doi.org/10.1212/WNL.58.suppl_1.S1] [PMID: 11909980]
[17]
Seeman, P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse, 2015, 69(4), 183-189.
[http://dx.doi.org/10.1002/syn.21805] [PMID: 25645960]
[18]
Jenni, N.L.; Larkin, J.D.; Floresco, S.B. Prefrontal dopamine D1 and D2 receptors regulate dissociable aspects of decision making via distinct ventral striatal and amygdalar circuits. J. Neurosci., 2017, 37(26), 6200-6213.
[http://dx.doi.org/10.1523/JNEUROSCI.0030-17.2017] [PMID: 28546312]
[19]
Zhong, P.; Qin, L.; Yan, Z. Dopamine differentially regulates response dynamics of prefrontal cortical principal neurons and interneurons to optogenetic stimulation of inputs from ventral tegmental area. Cereb. Cortex, 2020, 30(8), 4402-4409.
[http://dx.doi.org/10.1093/cercor/bhaa027] [PMID: 32236403]
[20]
Hosp, J.A.; Luft, A.R. Dopaminergic meso-cortical projections to m1: role in motor learning and motor cortex plasticity. Front. Neurol., 2013, 4, 145.
[http://dx.doi.org/10.3389/fneur.2013.00145] [PMID: 24109472]
[21]
Jose, P.A.; Raymond, J.R.; Bates, M.D.; Aperia, A.; Felder, R.A.; Carey, R.M. The renal dopamine receptors. J. Am. Soc. Nephrol., 1992, 2(8), 1265-1278.
[http://dx.doi.org/10.1681/ASN.V281265] [PMID: 1627751]
[22]
Contreras, F.; Fouillioux, C.; Bolívar, A.; Simonovis, N.; Hernández-Hernández, R.; Armas-Hernandez, M.J.; Velasco, M. Dopamine, hypertension and obesity. J. Hum. Hypertens., 2002, 16(S1)(Suppl. 1), S13-S17.
[http://dx.doi.org/10.1038/sj.jhh.1001334] [PMID: 11986886]
[23]
Tonini, M.; Cipollina, L.; Poluzzi, E.; Crema, F.; Corazza, G.R.; De Ponti, F. Clinical implications of enteric and central D 2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment. Pharmacol. Ther., 2004, 19(4), 379-390.
[http://dx.doi.org/10.1111/j.1365-2036.2004.01867.x] [PMID: 14871277]
[24]
Yeh, T.; Yang, Y.; Chiu, N.; Yao, W.; Yeh, S.; Wu, J.; Chuang, J.; Chang, S. Correlation between striatal dopamine D2/D3 receptor binding and cardiovascular activity in healthy subjects. Am. J. Hypertens., 2006, 19(9), 964-969.
[http://dx.doi.org/10.1016/j.amjhyper.2006.03.005] [PMID: 16942941]
[25]
Goldberg, L.I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol. Rev., 1972, 24(1), 1-29.
[PMID: 4554480]
[26]
Kohli, J.D. Peripheral dopamine receptors. Am. J. Hypertens., 1990, 3(6_Pt_2), 25S-28S.
[http://dx.doi.org/10.1093/ajh/3.6.25S] [PMID: 2143385]
[27]
Lokhandwala, M.F.; Jandhyala, B.S. The role of sympathetic nervous system in the vascular actions of dopamine. J. Pharmacol. Exp. Ther., 1979, 210(1), 120-126.
[PMID: 36477]
[28]
Polakowski, J.S.; Segreti, J.A.; Cox, B.F.; Hsieh, G.C.; Kolasa, T.; Moreland, R.B.; Brioni, J.D. Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clin. Exp. Pharmacol. Physiol., 2004, 31(12), 837-841.
[http://dx.doi.org/10.1111/j.1440-1681.2004.04095.x] [PMID: 15659045]
[29]
Antonini, A.; Poewe, W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol., 2007, 6(9), 826-829.
[http://dx.doi.org/10.1016/S1474-4422(07)70218-1] [PMID: 17706566]
[30]
Goetz, C.G. Dopaminergic agonists in the treatment of Parkinson’s disease. Neurology, 1990, 40(10)(Suppl. 3)
[31]
Uitti, R.J.; Ahlskog, J.E. Comparative Review of Dopamine Receptor Agonists in Parkinsonʼs Disease. CNS Drugs, 1996, 5(5), 369-388.
[http://dx.doi.org/10.2165/00023210-199605050-00006] [PMID: 26071049]
[32]
Müller, T.; Fritze, J. Fibrosis associated with dopamine agonist therapy in Parkinson’s disease. Clin. Neuropharmacol., 2003, 26(3), 109-111.
[http://dx.doi.org/10.1097/00002826-200305000-00001] [PMID: 12782910]
[33]
Hofmann, C.; Penner, U.; Dorow, R.; Pertz, H.H.; Jähnichen, S.; Horowski, R.; Latté, K.P.; Palla, D.; Schurad, B. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin. Neuropharmacol., 2006, 29(2), 80-86.
[http://dx.doi.org/10.1097/00002826-200603000-00005] [PMID: 16614540]
[34]
Lieberman, A.N.; Gopinathan, G.; Neophytides, A.; Leibowitz, M.; Walker, R.; Hiesiger, E. Bromocriptine and lisuride in Parkinson disease. Ann. Neurol., 1983, 13(1), 44-47.
[http://dx.doi.org/10.1002/ana.410130110] [PMID: 6830164]
[35]
Yamamoto, M.; Schapira, A.H.V. Dopamine agonists in Parkinson’s disease. Expert Rev. Neurother., 2008, 8(4), 671-677.
[http://dx.doi.org/10.1586/14737175.8.4.671] [PMID: 18416667]
[36]
Grünblatt, E.; Mandel, S.; Maor, G.; Youdim, M.B.H. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem., 2001, 77(1), 146-156.
[http://dx.doi.org/10.1046/j.1471-4159.2001.t01-1-00227.x] [PMID: 11279270]
[37]
Rose, S.; Scheller, D.K.A.; Breidenbach, A.; Smith, L.; Jackson, M.; Stockwell, K.; Jenner, P. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behav. Pharmacol., 2007, 18(2), 155-160.
[http://dx.doi.org/10.1097/FBP.0b013e3280ebb400] [PMID: 17351422]
[38]
Schmidt, W.J.; Lebsanft, H.; Heindl, M.; Gerlach, M.; Gruenblatt, E.; Riederer, P.; Mayerhofer, A.; Scheller, D.K.A. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J. Neural Transm. (Vienna), 2008, 115(10), 1385-1392.
[http://dx.doi.org/10.1007/s00702-008-0102-z] [PMID: 18726139]
[39]
Mierau, J.; Schingnitz, G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur. J. Pharmacol., 1992, 215(2-3), 161-170.
[http://dx.doi.org/10.1016/0014-2999(92)90024-X] [PMID: 1356788]
[40]
Domino, E.F.; Ni, L.; Zhang, H.; Kohno, Y.; Sasa, M. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys. Eur. J. Pharmacol., 1997, 325(2-3), 137-144.
[http://dx.doi.org/10.1016/S0014-2999(97)00129-5] [PMID: 9163560]
[41]
Hubble, J.P. Pre-clinical studies of pramipexole: clinical relevance. Eur. J. Neurol., 2000, 7(Suppl. 1), 15-20.
[http://dx.doi.org/10.1046/j.1468-1331.2000.0070s1015.x] [PMID: 11054154]
[42]
Fukuzaki, K.; Kamenosono, T.; Kitazumi, K.; Nagata, R. Effects of ropinirole on motor behavior in MPTP-treated common marmosets. Pharmacol. Biochem. Behav., 2000, 67(1), 121-129.
[http://dx.doi.org/10.1016/S0091-3057(00)00305-1] [PMID: 11113491]
[43]
Lane, E.L.; Dunnett, S.B. Pre-treatment with dopamine agonists influence l-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behav. Brain Res., 2010, 213(1), 66-72.
[http://dx.doi.org/10.1016/j.bbr.2010.04.034] [PMID: 20434491]
[44]
Grünblatt, E.; Mandel, S.; Berkuzki, T.; Youdim, M.B. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord., 1999, 14(4), 612-618.
[http://dx.doi.org/10.1002/1531-8257(199907)14:4<612:AID-MDS1010>3.0.CO;2-6] [PMID: 10435498]
[45]
Iravani, M.M.; Haddon, C.O.; Cooper, J.M.; Jenner, P.; Schapira, A.H. Pramipexole protects against MPTP toxicity in non-human primates. J. Neurochem., 2006, 96(5), 1315-1321.
[http://dx.doi.org/10.1111/j.1471-4159.2005.03625.x] [PMID: 16464239]
[46]
Wang, Y.; Yu, X.; Zhang, P.; Ma, Y.; Wang, L.; Xu, H.; Sui, D. Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson’s disease. J. Pharmacol. Sci., 2018, 138(1), 31-37.
[http://dx.doi.org/10.1016/j.jphs.2018.08.008] [PMID: 30241783]
[47]
Scheller, D.; Stichel-Gunkel, C.; Lübbert, H.; Porras, G.; Ravenscroft, P.; Hill, M.; Bezard, E. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson’s disease. Neurosci. Lett., 2008, 432(1), 30-34.
[http://dx.doi.org/10.1016/j.neulet.2007.12.001] [PMID: 18162314]
[48]
Gray, D.L.; Allen, J.A.; Mente, S.; O’Connor, R.E.; DeMarco, G.J.; Efremov, I.; Tierney, P.; Volfson, D.; Davoren, J.; Guilmette, E.; Salafia, M.; Kozak, R.; Ehlers, M.D. Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor. Nat. Commun., 2018, 9(1), 674.
[http://dx.doi.org/10.1038/s41467-017-02776-7] [PMID: 29445200]
[49]
Mailman, R.B.; Yang, Y.; Huang, X. D1, not D2, dopamine receptor activation dramatically improves MPTP-induced parkinsonism unresponsive to levodopa. Eur. J. Pharmacol., 2021, 892, 173760.
[http://dx.doi.org/10.1016/j.ejphar.2020.173760] [PMID: 33279520]
[50]
Goulet, M.; Madras, B.K.D.D. (1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Ther., 2000, 292(2), 714-724.
[PMID: 10640310]
[51]
Davoren, J.E.; Nason, D.; Coe, J.; Dlugolenski, K.; Helal, C.; Harris, A.R.; LaChapelle, E.; Liang, S.; Liu, Y.; O’Connor, R.; Orozco, C.C.; Rai, B.K.; Salafia, M.; Samas, B.; Xu, W.; Kozak, R.; Gray, D. Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization. J. Med. Chem., 2018, 61(24), 11384-11397.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01622] [PMID: 30431269]
[52]
Jenner, P.; Katzenschlager, R. Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat. Disord., 2016, 33(Suppl. 1), S13-S21.
[http://dx.doi.org/10.1016/j.parkreldis.2016.12.003] [PMID: 27979722]
[53]
Boyle, A.; Ondo, W. Role of apomorphine in the treatment of Parkinson’s disease. CNS Drugs, 2015, 29(2), 83-89.
[http://dx.doi.org/10.1007/s40263-014-0221-z] [PMID: 25676564]
[54]
Titova, N.; Chaudhuri, K.R. Apomorphine therapy in Parkinson’s disease and future directions. Parkinsonism Relat. Disord., 2016, 33(Suppl. 1), S56-S60.
[http://dx.doi.org/10.1016/j.parkreldis.2016.11.013] [PMID: 27913125]
[55]
Perez-Lloret, S. Apomorphine for the treatment of refractory motor fluctuations in late stage Parkinson’s disease: an old drug revisited. Eur. J. Neurol., 2013, 20(11), 1427-1428.
[http://dx.doi.org/10.1111/ene.12113] [PMID: 23398475]
[56]
Trenkwalder, C.; Chaudhuri, K.R.; García Ruiz, P.J.; LeWitt, P.; Katzenschlager, R.; Sixel-Döring, F.; Henriksen, T.; Sesar, Á.; Poewe, W.; Baker, M.; Ceballos-Baumann, A.; Deuschl, G.; Drapier, S.; Ebersbach, G.; Evans, A.; Fernandez, H.; Isaacson, S.; van Laar, T.; Lees, A.; Lewis, S.; Martínez Castrillo, J.C.; Martinez-Martin, P.; Odin, P.; O’Sullivan, J.; Tagaris, G.; Wenzel, K. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease – Clinical practice recommendations. Parkinsonism Relat. Disord., 2015, 21(9), 1023-1030.
[http://dx.doi.org/10.1016/j.parkreldis.2015.06.012] [PMID: 26189414]
[57]
Katzenschlager, R.; Poewe, W.; Rascol, O.; Trenkwalder, C.; Deuschl, G.; Chaudhuri, K.R.; Henriksen, T.; van Laar, T.; Spivey, K.; Vel, S.; Staines, H.; Lees, A. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol., 2018, 17(9), 749-759.
[http://dx.doi.org/10.1016/S1474-4422(18)30239-4] [PMID: 30055903]
[58]
Grosset, K.A.; Malek, N.; Morgan, F.; Grosset, D.G. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing ‘off’ periods in patients with established Parkinson’s disease. Eur. J. Neurol., 2013, 20(11), 1445-1450.
[http://dx.doi.org/10.1111/ene.12091] [PMID: 23350812]
[59]
Grosset, K.A.; Malek, N.; Morgan, F.; Grosset, D.G. Inhaled apomorphine in patients with ‘on-off’ fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study. J. Parkinsons Dis., 2013, 3(1), 31-37.
[http://dx.doi.org/10.3233/JPD-120142] [PMID: 23938309]
[60]
Grosset, K.A.; Malek, N.; Morgan, F.; Grosset, D.G. Inhaled dry powder apomorphine (VR040) for ‘off ’ periods in Parkinson’s disease: an in-clinic double-blind dose ranging study. Acta Neurol. Scand., 2013, 128(3), 166-171.
[http://dx.doi.org/10.1111/ane.12107] [PMID: 23527823]
[61]
Hauser, R.A.; Olanow, C.W.; Dzyngel, B.; Bilbault, T.; Shill, H.; Isaacson, S.; Dubow, J.; Agro, A. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov. Disord., 2016, 31(9), 1366-1372.
[http://dx.doi.org/10.1002/mds.26697] [PMID: 27430123]
[62]
Olanow, C.W.; Factor, S.A.; Espay, A.J.; Hauser, R.A.; Shill, H.A.; Isaacson, S.; Pahwa, R.; Leinonen, M.; Bhargava, P.; Sciarappa, K.; Navia, B.; Blum, D. xx, Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol., 2020, 19(2), 135-144.
[http://dx.doi.org/10.1016/S1474-4422(19)30396-5] [PMID: 31818699]
[63]
Hui, J.S.; Fox, S.H.; Neeson, W.; Bhargava, P.; Pappert, E.; Blum, D.; Navia, B. Open-label titration of apomorphine sublingual film in patients with Parkinson’s disease and “OFF” episodes. Parkinsonism Relat. Disord., 2020, 79, 110-116.
[http://dx.doi.org/10.1016/j.parkreldis.2020.08.028] [PMID: 32927285]
[64]
Olanow, C.W.; Poewe, W.; Rascol, O.; Stocchi, F. ON‐DEMAND Therapy for OFF Episodes in Parkinson’s Disease. Mov. Disord., 2021, 36(10), 2244-2253.
[http://dx.doi.org/10.1002/mds.28726] [PMID: 34363424]
[65]
Alegret, M.; Valldeoriola, F.; Martí, M.; Pilleri, M.; Junqué, C.; Rumià, J.; Tolosa, E. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov. Disord., 2004, 19(12), 1463-1469.
[http://dx.doi.org/10.1002/mds.20237] [PMID: 15390065]
[66]
Martinez-Martin, P.; Reddy, P.; Antonini, A.; Henriksen, T.; Katzenschlager, R.; Odin, P.; Todorova, A.; Naidu, Y.; Tluk, S.; Chandiramani, C.; Martin, A.; Chaudhuri, K.R. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J. Parkinsons Dis., 2011, 1(2), 197-203.
[http://dx.doi.org/10.3233/JPD-2011-11037] [PMID: 23934921]
[67]
Lefaucheur, R.; Berthelot, L.; Sénant, J.; Borden, A.; Maltête, D. Acute genital pain during non-motor fluctuations improved by apomorphine. Mov. Disord., 2013, 28(5), 687-688.
[http://dx.doi.org/10.1002/mds.25379] [PMID: 23389920]
[68]
Todorova, A.; Ray, C.K. Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord., 2013, 19(12), 1073-1078.
[http://dx.doi.org/10.1016/j.parkreldis.2013.08.012] [PMID: 24051336]
[69]
Müller, T. An evaluation of subcutaneous apomorphine for the treatment of Parkinson’s disease. Expert Opin. Pharmacother., 2020, 21(14), 1659-1665.
[http://dx.doi.org/10.1080/14656566.2020.1787379] [PMID: 32640853]
[70]
Martinez-Martin, P.; Reddy, P.; Katzenschlager, R.; Antonini, A.; Todorova, A.; Odin, P.; Henriksen, T.; Martin, A.; Calandrella, D.; Rizos, A.; Bryndum, N.; Glad, A.; Dafsari, H.S.; Timmermann, L.; Ebersbach, G.; Kramberger, M.G.; Samuel, M.; Wenzel, K.; Tomantschger, V.; Storch, A.; Reichmann, H.; Pirtosek, Z.; Trost, M.; Svenningsson, P.; Palhagen, S.; Volkmann, J.; Chaudhuri, K.R. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov. Disord., 2015, 30(4), 510-516.
[http://dx.doi.org/10.1002/mds.26067] [PMID: 25382161]
[71]
Rosa-Grilo, M.; Qamar, M.A.; Evans, A.; Chaudhuri, K.R. The efficacy of apomorphine – A non-motor perspective. Parkinsonism Relat. Disord., 2016, 33(Suppl. 1), S28-S35.
[http://dx.doi.org/10.1016/j.parkreldis.2016.11.020] [PMID: 27939325]
[72]
Carbone, F.; Djamshidian, A.; Seppi, K.; Poewe, W. Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs, 2019, 33(9), 905-918.
[http://dx.doi.org/10.1007/s40263-019-00661-z] [PMID: 31473980]
[73]
Factor, S.A.; Brown, D.L.; Molho, E.S. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov. Disord., 2000, 15(1), 167-169.
[http://dx.doi.org/10.1002/1531-8257(200001)15:1<167:AID-MDS1029>3.0.CO;2-8] [PMID: 10634261]
[74]
Moore, T.J.; Glenmullen, J.; Mattison, D.R. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern. Med., 2014, 174(12), 1930-1933.
[http://dx.doi.org/10.1001/jamainternmed.2014.5262] [PMID: 25329919]
[75]
Barbosa, P.; Lees, A.J.; Magee, C.; Djamshidian, A.; Warner, T.T. A retrospective evaluation of the frequency of impulsive compulsive behaviors in Parkinson’s disease patients treated with continuous waking day apomorphine pumps. Mov. Disord. Clin. Pract. (Hoboken), 2017, 4(3), 323-328.
[http://dx.doi.org/10.1002/mdc3.12416] [PMID: 30363495]
[76]
Torti, M.; Bravi, D.; Vacca, L.; Stocchi, F. Are all dopamine agonists essentially the same? Drugs, 2019, 79(7), 693-703.
[http://dx.doi.org/10.1007/s40265-019-01103-2] [PMID: 30968290]
[77]
Elshoff, J.P.; Cawello, W.; Andreas, J.O.; Mathy, F.X.; Braun, M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs, 2015, 75(5), 487-501.
[http://dx.doi.org/10.1007/s40265-015-0377-y] [PMID: 25795100]
[78]
Frampton, J.E. Rotigotine Transdermal Patch: A review in Parkinson’s disease. CNS Drugs, 2019, 33(7), 707-718.
[http://dx.doi.org/10.1007/s40263-019-00646-y] [PMID: 31243728]
[79]
Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch. Neurol., 2003, 60(12), 1721-1728.
[http://dx.doi.org/10.1001/archneur.60.12.1721] [PMID: 14676046]
[80]
Jankovic, J.; Watts, R.L.; Martin, W.; Boroojerdi, B. Transdermal Rotigotine. Arch. Neurol., 2007, 64(5), 676-682.
[http://dx.doi.org/10.1001/archneur.64.5.676] [PMID: 17502466]
[81]
Watts, R.L.; Jankovic, J.; Waters, C.; Rajput, A.; Boroojerdi, B.; Rao, J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology, 2007, 68(4), 272-276.
[http://dx.doi.org/10.1212/01.wnl.0000252355.79284.22] [PMID: 17202432]
[82]
Giladi, N.; Boroojerdi, B.; Korczyn, A.D.; Burn, D.J.; Clarke, C.E.; Schapira, A.H.V. Rotigotine transdermal patch in early Parkinson’s disease: A randomized, double-blind, controlled study versus placebo and ropinirole. Mov. Disord., 2007, 22(16), 2398-2404.
[http://dx.doi.org/10.1002/mds.21741] [PMID: 17935234]
[83]
Zhang, Z.X.; Shang, H.F.; Hu, X.; Chen, S.; Zhao, Z.; Du, X.; Surmann, E.; Bauer, L.; Asgharnejad, M. Rotigotine transdermal patch in Chinese patients with early Parkinson’s disease: A randomized, double-blind, placebo-controlled pivotal study. Parkinsonism Relat. Disord., 2016, 28, 49-55.
[http://dx.doi.org/10.1016/j.parkreldis.2016.04.022] [PMID: 27172830]
[84]
Mizuno, Y.; Nomoto, M.; Kondo, T.; Hasegawa, K.; Murata, M.; Takeuchi, M.; Ikeda, J.; Tomida, T.; Hattori, N. Transdermal rotigotine in early stage Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Mov. Disord., 2013, 28(10), 1447-1450.
[http://dx.doi.org/10.1002/mds.25537] [PMID: 23801585]
[85]
Zhang, Z.X.; Liu, C.F.; Tao, E.X.; Shao, M.; Liu, Y.M.; Wang, J.; Asgharnejad, M.; Xue, H.B.; Surmann, E.; Bauer, L. Rotigotine transdermal patch in Chinese patients with advanced Parkinson’s disease: A randomized, double-blind, placebo-controlled pivotal study. Parkinsonism Relat. Disord., 2017, 44, 6-12.
[http://dx.doi.org/10.1016/j.parkreldis.2017.08.015] [PMID: 28827011]
[86]
Nomoto, M.; Mizuno, Y.; Kondo, T.; Hasegawa, K.; Murata, M.; Takeuchi, M.; Ikeda, J.; Tomida, T.; Hattori, N. Transdermal rotigotine in advanced Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. J. Neurol., 2014, 261(10), 1887-1893.
[http://dx.doi.org/10.1007/s00415-014-7427-3] [PMID: 25022939]
[87]
Nicholas, A.P.; Borgohain, R.; Chaná, P.; Surmann, E.; Thompson, E.L.; Bauer, L.; Whitesides, J.; Elmer, L.W. A randomized study of rotigotine dose response on ‘off’ time in advanced Parkinson’s disease. J. Parkinsons Dis., 2014, 4(3), 361-373.
[http://dx.doi.org/10.3233/JPD-130320] [PMID: 24643203]
[88]
LeWitt, P.A.; Lyons, K.E.; Pahwa, R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology, 2007, 68(16), 1262-1267.
[http://dx.doi.org/10.1212/01.wnl.0000259516.61938.bb] [PMID: 17438216]
[89]
Poewe, W.H.; Rascol, O.; Quinn, N.; Tolosa, E.; Oertel, W.H.; Martignoni, E.; Rupp, M.; Boroojerdi, B. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol., 2007, 6(6), 513-520.
[http://dx.doi.org/10.1016/S1474-4422(07)70108-4] [PMID: 17509486]
[90]
Mizuno, Y.; Nomoto, M.; Hasegawa, K.; Hattori, N.; Kondo, T.; Murata, M.; Takeuchi, M.; Takahashi, M.; Tomida, T. Rotigotine vs ropinirole in advanced stage Parkinson’s disease: A double-blind study. Parkinsonism Relat. Disord., 2014, 20(12), 1388-1393.
[http://dx.doi.org/10.1016/j.parkreldis.2014.10.005] [PMID: 25455692]
[91]
Giladi, N.; Nicholas, A.P.; Asgharnejad, M.; Dohin, E.; Woltering, F.; Bauer, L.; Poewe, W. Efficacy of rotigotine at different stages of Parkinson’s disease symptom severity and disability: A post hoc analysis according to baseline hoehn and yahr stage. J. Parkinsons Dis., 2016, 6(4), 741-749.
[http://dx.doi.org/10.3233/JPD-160847] [PMID: 27567886]
[92]
Müller, T.; Tolosa, E.; Badea, L.; Asgharnejad, M.; Grieger, F.; Markowitz, M.; Nondonfaz, X.; Bauer, L.; Timmermann, L. An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson’s disease. J. Neural Transm. (Vienna), 2018, 125(6), 953-963.
[http://dx.doi.org/10.1007/s00702-018-1860-x] [PMID: 29484495]
[93]
Giladi, N.; Boroojerdi, B.; Surmann, E. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson’s disease. J. Neural Transm. (Vienna), 2013, 120(9), 1321-1329.
[http://dx.doi.org/10.1007/s00702-013-1001-5] [PMID: 23508526]
[94]
Elmer, L.W.; Surmann, E.; Boroojerdi, B.; Jankovic, J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: A prospective, open-label extension study. Parkinsonism Relat. Disord., 2012, 18(5), 488-493.
[http://dx.doi.org/10.1016/j.parkreldis.2012.01.008] [PMID: 22326237]
[95]
LeWitt, P.A.; Boroojerdi, B.; Surmann, E.; Poewe, W. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J. Neural Transm. (Vienna), 2013, 120(7), 1069-1081.
[http://dx.doi.org/10.1007/s00702-012-0925-5] [PMID: 23208198]
[96]
Perez-Lloret, S.; Verónica Rey, M.; Lucca Ratti, P.; Rascol, O. Rotigotine transdermal patch for the treatment of Parkinson’s Disease. Fundam. Clin. Pharmacol., 2013, 27(1), 81-95.
[http://dx.doi.org/10.1111/j.1472-8206.2012.01028.x] [PMID: 22320451]
[97]
Giladi, N.; Ghys, L.; Surmann, E.; Boroojerdi, B.; Jankovic, J. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson’s disease. Parkinsonism Relat. Disord., 2014, 20(12), 1345-1351.
[http://dx.doi.org/10.1016/j.parkreldis.2014.09.016] [PMID: 25444083]
[98]
Bhidayasiri, R.; Sringean, J.; Chaiwong, S.; Anan, C.; Penkeaw, N.; Leaknok, A.; Boonpang, K.; Saksornchai, K.; Rattanachaisit, W.; Thanawattano, C.; Jagota, P. Rotigotine for nocturnal hypokinesia in Parkinson’s disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor. Parkinsonism Relat. Disord., 2017, 44, 124-128.
[http://dx.doi.org/10.1016/j.parkreldis.2017.08.010] [PMID: 28818560]
[99]
Trenkwalder, C.; Kies, B.; Rudzinska, M.; Fine, J.; Nikl, J.; Honczarenko, K.; Dioszeghy, P.; Hill, D.; Anderson, T.; Myllyla, V.; Kassubek, J.; Steiger, M.; Zucconi, M.; Tolosa, E.; Poewe, W.; Surmann, E.; Whitesides, J.; Boroojerdi, B.; Chaudhuri, K.R. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: A double‐blind, randomized, placebo‐controlled study (recover). Mov. Disord., 2011, 26(1), 90-99.
[http://dx.doi.org/10.1002/mds.23441] [PMID: 21322021]
[100]
Ghys, L.; Surmann, E.; Whitesides, J.; Boroojerdi, B. Effect of rotigotine on sleep and quality of life in Parkinson’s disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin. Pharmacother., 2011, 12(13), 1985-1998.
[http://dx.doi.org/10.1517/14656566.2011.604031] [PMID: 21790503]
[101]
Pierantozzi, M.; Placidi, F.; Liguori, C.; Albanese, M.; Imbriani, P.; Marciani, M.G.; Mercuri, N.B.; Stanzione, P.; Stefani, A. Rotigotine may improve sleep architecture in Parkinson’s disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med., 2016, 21, 140-144.
[http://dx.doi.org/10.1016/j.sleep.2016.01.016] [PMID: 27448485]
[102]
Kassubek, J.; Chaudhuri, K.R.; Zesiewicz, T.; Surmann, E.; Boroojerdi, B.; Moran, K.; Ghys, L.; Trenkwalder, C. Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hocanalysis of the RECOVER study. BMC Neurol., 2014, 14(1), 42.
[http://dx.doi.org/10.1186/1471-2377-14-42] [PMID: 24602411]
[103]
Rascol, O.; Zesiewicz, T.; Chaudhuri, K.R.; Asgharnejad, M.; Surmann, E.; Dohin, E.; Nilius, S.; Bauer, L. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson’s disease-associated chronic pain. J. Clin. Pharmacol., 2016, 56(7), 852-861.
[http://dx.doi.org/10.1002/jcph.678] [PMID: 26626320]
[104]
Valldeoriola, F.; Salvador, A.; Gómez-Arguelles, J.M.; Marey, J.; Moya, M.; Ayuga, Á.; Ramírez, F. The effects of transdermal rotigotine on non-motor symptoms of Parkinson’s disease: a multicentre, observational, retrospective, post-marketing study. Int. J. Neurosci., 2018, 128(4), 369-375.
[http://dx.doi.org/10.1080/00207454.2017.1387111] [PMID: 29249180]
[105]
Hirano, M.; Isono, C.; Sakamoto, H.; Ueno, S.; Kusunoki, S.; Nakamura, Y. Rotigotine transdermal patch improves swallowing in dysphagic patients with Parkinson’s disease. Dysphagia, 2015, 30(4), 452-456.
[http://dx.doi.org/10.1007/s00455-015-9622-5] [PMID: 25966655]
[106]
Chung, S.J.; Asgharnejad, M.; Bauer, L.; Ramirez, F.; Jeon, B. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson’s disease. Expert Opin. Pharmacother., 2016, 17(11), 1453-1461.
[http://dx.doi.org/10.1080/14656566.2016.1202917] [PMID: 27322571]
[107]
Wang, H.; Wang, L.; He, Y.; Yu, G. Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson’s disease: A meta-analysis of randomized placebo-controlled trials. J. Neurol. Sci., 2018, 393, 31-38.
[http://dx.doi.org/10.1016/j.jns.2018.08.003] [PMID: 30099246]
[108]
Raeder, V.; Boura, I.; Leta, V.; Jenner, P.; Reichmann, H.; Trenkwalder, C.; Klingelhoefer, L.; Chaudhuri, K.R. Rotigotine transdermal patch for motor and non-motor Parkinson’s disease: A review of 12 years’ clinical experience. CNS Drugs, 2021, 35(2), 215-231.
[http://dx.doi.org/10.1007/s40263-020-00788-4] [PMID: 33559846]
[109]
Antonini, A.; Barone, P.; Ceravolo, R.; Fabbrini, G.; Tinazzi, M.; Abbruzzese, G. Role of pramipexole in the management of Parkinson’s disease. CNS Drugs, 2010, 24(10), 829-841.
[http://dx.doi.org/10.2165/11585090-000000000-00000] [PMID: 20839895]
[110]
Rios, C.; Boll, M-C.; Alcaraz-Zubeldia, M. Medical management of Parkinson’s disease: focus on neuroprotection. Curr. Neuropharmacol., 2011, 9(2), 350-359.
[http://dx.doi.org/10.2174/157015911795596577] [PMID: 22131943]
[111]
Schapira, A.H.V.; Barone, P.; Hauser, R.A.; Mizuno, Y.; Rascol, O.; Busse, M.; Salin, L.; Juhel, N.; Poewe, W. Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial. Neurology, 2011, 77(8), 767-774.
[http://dx.doi.org/10.1212/WNL.0b013e31822affdb] [PMID: 21832216]
[112]
Poewe, W.; Rascol, O.; Barone, P.; Hauser, R.A.; Mizuno, Y.; Haaksma, M.; Salin, L.; Juhel, N.; Schapira, A.H.V. Extended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trial. Neurology, 2011, 77(8), 759-766.
[http://dx.doi.org/10.1212/WNL.0b013e31822affb0] [PMID: 21832218]
[113]
Schapira, A.H.V.; McDermott, M.P.; Barone, P.; Comella, C.L.; Albrecht, S.; Hsu, H.H.; Massey, D.H.; Mizuno, Y.; Poewe, W.; Rascol, O.; Marek, K. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol., 2013, 12(8), 747-755.
[http://dx.doi.org/10.1016/S1474-4422(13)70117-0] [PMID: 23726851]
[114]
Olanow, C.W.; Kieburtz, K.; Leinonen, M.; Elmer, L.; Giladi, N.; Hauser, R.A.; Klepiskaya, O.S.; Kreitzman, D.L.; Lew, M.F.; Russell, D.S.; Kadosh, S.; Litman, P.; Friedman, H.; Linvah, N. the PB Study Group, A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson’s disease. Mov. Disord., 2017, 32(5), 783-789.
[http://dx.doi.org/10.1002/mds.26941] [PMID: 28370340]
[115]
Barone, P.; Poewe, W.; Albrecht, S.; Debieuvre, C.; Massey, D.; Rascol, O.; Tolosa, E.; Weintraub, D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol., 2010, 9(6), 573-580.
[http://dx.doi.org/10.1016/S1474-4422(10)70106-X] [PMID: 20452823]
[116]
Jiang, D.Q.; Jiang, L.L.; Wang, Y.; Li, M.X. The role of pramipexole in the treatment of patients with depression and Parkinson’s disease: A meta-analysis of randomized controlled trials. Asian J. Psychiatr., 2021, 61, 102691.
[http://dx.doi.org/10.1016/j.ajp.2021.102691] [PMID: 33992852]
[117]
Seppi, K.; Ray Chaudhuri, K.; Coelho, M.; Fox, S.H.; Katzenschlager, R.; Perez Lloret, S.; Weintraub, D.; Sampaio, C.; Chahine, L.; Hametner, E-M.; Heim, B.; Lim, S-Y.; Poewe, W.; Djamshidian-Tehrani, A. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence‐based medicine review. Mov. Disord., 2019, 34(2), 180-198.
[http://dx.doi.org/10.1002/mds.27602] [PMID: 30653247]
[118]
Xiang, W.; Sun, Y.Q.; Teoh, H.C. Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations. Drug Des. Devel. Ther., 2018, 12, 2017-2024.
[http://dx.doi.org/10.2147/DDDT.S160300] [PMID: 30013321]
[119]
Zhou, H.; Li, S.; Yu, H.; Sun, S.; Wan, X.; Zhu, X.; Liu, C.F.; Chen, L.; Xiang, W.; Sun, Y.; Chen, H.; Chen, S. Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson’s Disease: A Pilot Study. Parkinsons Dis., 2021, 2021, 1-12.
[http://dx.doi.org/10.1155/2021/8834950] [PMID: 33763199]
[120]
Weng, J.J.; Wang, L.H.; Zhu, H.; Xu, W.R.; Wei, Y.M.; Wang, Z.Y.; Yu, W.J.; Li, H.F. Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study. Neuropsychiatr. Dis. Treat., 2019, 15, 2195-2203.
[http://dx.doi.org/10.2147/NDT.S205933] [PMID: 31496702]
[121]
Shen, T.; Ye, R.; Zhang, B. Efficacy and safety of pramipexole extended-release in Parkinson’s disease: a review based on meta-analysis of randomized controlled trials. Eur. J. Neurol., 2017, 24(6), 835-843.
[http://dx.doi.org/10.1111/ene.13303] [PMID: 28480621]
[122]
Müller, T.; Przuntek, H.; Kuhlmann, A. Loss of color vision during long-term treatment with pramipexole. J. Neurol., 2003, 250(1), 101-102.
[http://dx.doi.org/10.1007/s00415-003-0915-5] [PMID: 12528002]
[123]
Mokhles, M.M.; Trifirò, G.; Dieleman, J.P.; Haag, M.D.; van Soest, E.M.; Verhamme, K.M.C.; Mazzaglia, G.; Herings, R.; de Luise, C.; Ross, D.; Brusselle, G.; Colao, A.; Haverkamp, W.; Schade, R.; van Camp, G.; Zanettini, R.; Sturkenboom, M.C.J.M. The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacol. Res., 2012, 65(3), 358-364.
[http://dx.doi.org/10.1016/j.phrs.2011.11.009] [PMID: 22123498]
[124]
Renoux, C.; Dell’Aniello, S.; Brophy, J.M.; Suissa, S. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol. Drug Saf., 2012, 21(1), 34-41.
[http://dx.doi.org/10.1002/pds.2267] [PMID: 22109939]
[125]
Contin, M.; Lopane, G.; Mohamed, S.; Calandra-Buonaura, G.; Capellari, S.; De Massis, P.; Nassetti, S.; Perrone, A.; Riva, R.; Sambati, L.; Scaglione, C.; Cortelli, P. Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson’s disease. Parkinsonism Relat. Disord., 2019, 61, 111-117.
[http://dx.doi.org/10.1016/j.parkreldis.2018.11.007] [PMID: 30446407]
[126]
Zhu, J.; Chen, M. The effect and safety of ropinirole in the treatment of Parkinson disease. Medicine (Baltimore), 2021, 100(46), e27653.
[http://dx.doi.org/10.1097/MD.0000000000027653] [PMID: 34797288]
[127]
Stocchi, F.; Hersh, B.P.; Scott, B.L.; Nausieda, P.A.; Giorgi, L. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr. Med. Res. Opin., 2008, 24(10), 2883-2895.
[http://dx.doi.org/10.1185/03007990802387130] [PMID: 18768106]
[128]
Watts, R.L.; Lyons, K.E.; Pahwa, R.; Sethi, K.; Stern, M.; Hauser, R.A.; Olanow, W.; Gray, A.M.; Adams, B.; Earl, N.L. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov. Disord., 2010, 25(7), 858-866.
[http://dx.doi.org/10.1002/mds.22890] [PMID: 20461803]
[129]
Pahwa, R.; Stacy, M.A.; Factor, S.A.; Lyons, K.E.; Stocchi, F.; Hersh, B.P.; Elmer, L.W.; Truong, D.D.; Earl, N.L. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology, 2007, 68(14), 1108-1115.
[http://dx.doi.org/10.1212/01.wnl.0000258660.74391.c1] [PMID: 17404192]
[130]
Stocchi, F.; Giorgi, L.; Hunter, B.; Schapira, A.H.V. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov. Disord., 2011, 26(7), 1259-1265.
[http://dx.doi.org/10.1002/mds.23498] [PMID: 21469195]
[131]
Hattori, N.; Mochizuki, H.; Hasegawa, K.; Nomoto, M.; Uchida, E.; Terahara, T.; Okawa, K.; Fukuta, H. Ropinirole patch Versus placebo, Ropinirole extended‐release tablet in advanced Parkinson’s disease. Mov. Disord., 2020, 35(9), 1565-1573.
[http://dx.doi.org/10.1002/mds.28071] [PMID: 32396257]
[132]
Mochizuki, H.; Hattori, N.; Hasegawa, K.; Nomoto, M.; Uchida, E.; Terahara, T.; Okawa, K.; Fukuta, H. Long-term study of ropinirole patch in Parkinson’s disease patients with/without basal l-dopa. Parkinsonism Relat. Disord., 2021, 83, 105-109.
[http://dx.doi.org/10.1016/j.parkreldis.2020.12.023] [PMID: 33497892]
[133]
Rektorova, I.; Balaz, M.; Svatova, J.; Zarubova, K.; Honig, I.; Dostal, V.; Sedlackova, S.; Nestrasil, I.; Mastik, J.; Bares, M.; Veliskova, J.; Dusek, L. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin. Neuropharmacol., 2008, 31(5), 261-266.
[http://dx.doi.org/10.1097/WNF.0b013e31815d25ce] [PMID: 18836343]
[134]
Ray Chaudhuri, K.; Martinez-Martin, P.; Rolfe, K.A.; Cooper, J.; Rockett, C.B.; Giorgi, L.; Ondo, W.G. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur. J. Neurol., 2012, 19(1), 105-113.
[http://dx.doi.org/10.1111/j.1468-1331.2011.03442.x] [PMID: 21699627]
[135]
Dušek, P.; Bušková, J.; Růžička, E.; Majerová, V.; Srp, A.; Jech, R.; Roth, J.; Šonka, K. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin. Neuropharmacol., 2010, 33(4), 186-190.
[http://dx.doi.org/10.1097/WNF.0b013e3181e71166] [PMID: 20661025]
[136]
Castro-Caldas, A.; Delwaide, P.; Jost, W.; Merello, M.; Williams, A.; Lamberti, P.; Aguilar, M.; Del Signore, S.; Cesaro, P. The Parkinson-Control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease. Mov. Disord., 2006, 21(4), 500-509.
[http://dx.doi.org/10.1002/mds.20750] [PMID: 16267842]
[137]
Millan, M.J. From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol. Ther., 2010, 128(2), 229-273.
[http://dx.doi.org/10.1016/j.pharmthera.2010.06.002] [PMID: 20600305]
[138]
Perez-Lloret, S.; Rascol, O. Piribedil for the treatment of motor and non-motor symptoms of Parkinson disease. CNS Drugs, 2016, 30(8), 703-717.
[http://dx.doi.org/10.1007/s40263-016-0360-5] [PMID: 27344665]
[139]
Rascol, O.; Azulay, J.P.; Blin, O.; Bonnet, A.M.; Brefel-Courbon, C.; Césaro, P.; Damier, P.; Debilly, B.; Durif, F.; Galitzky, M.; Grouin, J.M.; Pennaforte, S.; Villafane, G.; Yaici, S.; Agid, Y. Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo-controlled, randomized, double-blind, cross-over study. Mov. Disord., 2010, 25(3), 368-376.
[http://dx.doi.org/10.1002/mds.22922] [PMID: 20063435]
[140]
Thobois, S.; Lhommée, E.; Klinger, H.; Ardouin, C.; Schmitt, E.; Bichon, A.; Kistner, A.; Castrioto, A.; Xie, J.; Fraix, V.; Pelissier, P.; Chabardes, S.; Mertens, P.; Quesada, J.L.; Bosson, J.L.; Pollak, P.; Broussolle, E.; Krack, P. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain, 2013, 136(5), 1568-1577.
[http://dx.doi.org/10.1093/brain/awt067] [PMID: 23543483]
[141]
Eggert, K.; Öhlwein, C.; Kassubek, J.; Wolz, M.; Kupsch, A.; Ceballos-Baumann, A.; Ehret, R.; Polzer, U.; Klostermann, F.; Schwarz, J.; Fuchs, G.; Jost, W.; Albert, A.; Haag, A.; Hermsen, A.; Lohmüller, K.; Kuhn, K.; Wangemann, M.; Oertel, W.H. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin. Neuropharmacol., 2014, 37(4), 116-122.
[http://dx.doi.org/10.1097/WNF.0000000000000041] [PMID: 24992083]
[142]
Schrag, A.; Sauerbier, A.; Chaudhuri, K.R. New clinical trials for nonmotor manifestations of Parkinson’s disease. Mov. Disord., 2015, 30(11), 1490-1504.
[http://dx.doi.org/10.1002/mds.26415] [PMID: 26371623]
[143]
Papapetropoulos, S.; Liu, W.; Duvvuri, S.; Thayer, K.; Gray, D.L. Evaluation of D1/D5 partial agonist PF-06412562 in Parkinson’s disease following oral administration. Neurodegener. Dis., 2018, 18(5-6), 262-269.
[http://dx.doi.org/10.1159/000492498] [PMID: 30453303]
[144]
Huang, X.; Lewis, M.M.; Van Scoy, L.J.; De Jesus, S.; Eslinger, P.J.; Arnold, A.C.; Miller, A.J.; Fernandez-Mendoza, J.; Snyder, B.; Harrington, W.; Kong, L.; Wang, X.; Sun, D.; Delnomdedieu, M.; Duvvuri, S.; Mahoney, S.E.; Gray, D.L.; Mailman, R.B. The D1/D5 dopamine partial agonist PF-06412562 in advanced-stage Parkinson’s disease: A feasibility study. J. Parkinsons Dis., 2020, 10(4), 1515-1527.
[http://dx.doi.org/10.3233/JPD-202188] [PMID: 32986682]
[145]
Sohur, U.S.; Gray, D.L.; Duvvuri, S.; Zhang, Y.; Thayer, K.; Feng, G. Phase 1 Parkinson’s disease studies show the dopamine D1/D5 agonist PF-06649751 is safe and well tolerated. Neurol. Ther., 2018, 7(2), 307-319.
[http://dx.doi.org/10.1007/s40120-018-0114-z] [PMID: 30361858]
[146]
Riesenberg, R.; Werth, J.; Zhang, Y.; Duvvuri, S.; Gray, D. PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial. Ther. Adv. Neurol. Disord., 2020, 13.
[http://dx.doi.org/10.1177/1756286420911296] [PMID: 32201505]
[147]
Gurrell, R.; Duvvuri, S.; Sun, P.; DeMartinis, N. A phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel dopamine D1 receptor partial agonist, PF-06669571, in subjects with idiopathic Parkinson’s disease. Clin. Drug Investig., 2018, 38(6), 509-517.
[http://dx.doi.org/10.1007/s40261-018-0632-6] [PMID: 29478239]
[148]
Solla, P.; Fasano, A.; Cannas, A.; Marrosu, F. Suicide and dopamine agonist withdrawal syndrome in Parkinson’s disease. Mov. Disord., 2015, 30(13), 1859-1860.
[http://dx.doi.org/10.1002/mds.26443] [PMID: 26452673]
[149]
Nirenberg, M.J. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging, 2013, 30(8), 587-592.
[http://dx.doi.org/10.1007/s40266-013-0090-z] [PMID: 23686524]
[150]
Vargas, A.P.; Vaz, L.S.; Reuter, A.; Couto, C.M.; Costa Cardoso, F.E. Impulse control symptoms in patients with Parkinson’s disease: The influence of dopaminergic agonist. Parkinsonism Relat. Disord., 2019, 68, 17-21.
[http://dx.doi.org/10.1016/j.parkreldis.2019.06.019] [PMID: 31621612]
[151]
Weintraub, D.; Koester, J.; Potenza, M.N.; Siderowf, A.D.; Stacy, M.; Voon, V.; Whetteckey, J.; Wunderlich, G.R.; Lang, A.E. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol., 2010, 67(5), 589-595.
[http://dx.doi.org/10.1001/archneurol.2010.65] [PMID: 20457959]
[152]
Bastiaens, J.; Dorfman, B.J.; Christos, P.J.; Nirenberg, M.J. Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov. Disord., 2013, 28(3), 327-333.
[http://dx.doi.org/10.1002/mds.25291] [PMID: 23283708]
[153]
Grall-Bronnec, M.; Victorri-Vigneau, C.; Donnio, Y.; Leboucher, J.; Rousselet, M.; Thiabaud, E.; Zreika, N.; Derkinderen, P.; Challet-Bouju, G. Dopamine agonists and impulse control disorders: A complex association. Drug Saf., 2018, 41(1), 19-75.
[http://dx.doi.org/10.1007/s40264-017-0590-6] [PMID: 28861870]
[154]
Castro-Martínez, X.H.; García-Ruiz, P.J.; Martínez-García, C.; Martínez-Castrillo, J.C.; Vela, L.; Mata, M.; Martínez-Torres, I.; Feliz-Feliz, C.; Palau, F.; Hoenicka, J. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants. Parkinsonism Relat. Disord., 2018, 49, 100-103.
[http://dx.doi.org/10.1016/j.parkreldis.2018.01.010] [PMID: 29361389]
[155]
Garcia-Ruiz, P.J.; Martinez, C.J.C.; Alonso-Canovas, A.; Herranz, B.A.; Vela, L.; Sanchez, A.P.; Mata, M.; Olmedilla, G.N.; Mahillo, F.I. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J. Neurol. Neurosurg. Psychiatry, 2014, 85(8), 840-844.
[http://dx.doi.org/10.1136/jnnp-2013-306787] [PMID: 24434037]
[156]
Rizos, A.; Sauerbier, A.; Antonini, A.; Weintraub, D.; Martinez-Martin, P.; Kessel, B.; Henriksen, T.; Falup-Pecurariu, C.; Silverdale, M.; Durner, G.; Røkenes, K.K.; Grilo, M.; Odin, P.; Chaudhuri, K.R. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur. J. Neurol., 2016, 23(8), 1255-1261.
[http://dx.doi.org/10.1111/ene.13034] [PMID: 27170229]
[157]
Weintraub, D. Impulse control disorders in Parkinson’s disease: A 20‐year odyssey. Mov. Disord., 2019, 34(4), mds.27668.
[http://dx.doi.org/10.1002/mds.27668] [PMID: 30913337]
[158]
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: A multicenter study. Mov. Disord., 2008, 23(8), 1130-1136.
[159]
Corvol, J.C.; Artaud, F.; Cormier-Dequaire, F.; Rascol, O.; Durif, F.; Derkinderen, P.; Marques, A.R.; Bourdain, F.; Brandel, J.P.; Pico, F.; Lacomblez, L.; Bonnet, C.; Brefel-Courbon, C.; Ory-Magne, F.; Grabli, D.; Klebe, S.; Mangone, G.; You, H.; Mesnage, V.; Lee, P.C.; Brice, A.; Vidailhet, M.; Elbaz, A. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology, 2018, 91(3), e189-e201.
[http://dx.doi.org/10.1212/WNL.0000000000005816] [PMID: 29925549]
[160]
Micheli, F.E.; Giugni, J.C.; Espinosa, M.E.D.A.; Calvo, D.S.; Raina, G.B. Piribedil and pathological gambling in six parkinsonian patients. Arq. Neuropsiquiatr., 2015, 73(2), 115-118.
[http://dx.doi.org/10.1590/0004-282X20140212] [PMID: 25742580]
[161]
Samuel, M.; Rodriguez-Oroz, M.; Antonini, A.; Brotchie, J.M.; Ray, C.K.; Brown, R.G.; Galpern, W.R.; Nirenberg, M.J.; Okun, M.S.; Lang, A.E. Management of impulse control disorders in Parkinson’s disease: Controversies and future approaches. Mov. Disord., 2015, 30(2), 150-159.
[http://dx.doi.org/10.1002/mds.26099] [PMID: 25607799]
[162]
Chen, Q.; Weidner, R.; Vossel, S.; Weiss, P.H.; Fink, G.R. Neural mechanisms of attentional reorienting in three-dimensional space. J. Neurosci., 2012, 32(39), 13352-13362.
[http://dx.doi.org/10.1523/JNEUROSCI.1772-12.2012] [PMID: 23015426]
[163]
Chaudhuri, K.R.; Todorova, A.; Nirenberg, M.J.; Parry, M.; Martin, A.; Martinez-Martin, P.; Rizos, A.; Henriksen, T.; Jost, W.; Storch, A.; Ebersbach, G.; Reichmann, H.; Odin, P.; Antonini, A. A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson’s disease. Mov. Disord. Clin. Pract. (Hoboken), 2015, 2(2), 170-174.
[http://dx.doi.org/10.1002/mdc3.12141] [PMID: 30713891]
[164]
Yu, X.X.; Fernandez, H.H. Dopamine agonist withdrawal syndrome: A comprehensive review. J. Neurol. Sci., 2017, 374, 53-55.
[http://dx.doi.org/10.1016/j.jns.2016.12.070] [PMID: 28104232]
[165]
Szymanski, C.; Boey, S.; Hermida, J.S. Ropinirole-induced symptomatic sinus node dysfunction. Pacing Clin. Electrophysiol., 2008, 31(8), 1079-1082.
[http://dx.doi.org/10.1111/j.1540-8159.2008.01141.x] [PMID: 18684270]
[166]
Latt, M.D.; Lewis, S.; Zekry, O.; Fung, V.S.C. Factors to consider in the selection of dopamine agonists for older persons with Parkinson’s disease. Drugs Aging, 2019, 36(3), 189-202.
[http://dx.doi.org/10.1007/s40266-018-0629-0] [PMID: 30623310]
[167]
Fox, S.H.; Katzenschlager, R.; Lim, S.Y.; Ravina, B.; Seppi, K.; Coelho, M.; Poewe, W.; Rascol, O.; Goetz, C.G.; Sampaio, C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease. Mov. Disord., 2011, 26(S3)(Suppl. 3), S2-S41.
[http://dx.doi.org/10.1002/mds.23829] [PMID: 22021173]
[168]
Hauser, R.A.; LeWitt, P.A.; Comella, C.L. On demand therapy for Parkinson’s disease patients: Opportunities and choices. Postgrad. Med., 2021, 133(7), 721-727.
[http://dx.doi.org/10.1080/00325481.2021.1936087] [PMID: 34082655]
[169]
Perez-Lloret, S.; Rey, M.V.; Fabre, N.; Ory, F.; Spampinato, U.; Brefel-Courbon, C.; Montastruc, J.L.; Rascol, O. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin. Neuropharmacol., 2012, 35(6), 261-265.
[http://dx.doi.org/10.1097/WNF.0b013e31826e6e6d] [PMID: 23123689]
[170]
Ohta, K.; Osada, T. Rotigotine transdermal patch does not make Parkinson disease patients sleepy during daytime. Clin. Neuropharmacol., 2015, 38(6), 231-235.
[http://dx.doi.org/10.1097/WNF.0000000000000110] [PMID: 26536020]
[171]
Christmas, T.J.; Chapple, C.R.; Lees, A.J.; Kempster, P.A.; Frankel, J.P.; Stern, G.M.; Milroy, E.J.G. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet, 1988, 332(8626-8627), 1451-1453.
[http://dx.doi.org/10.1016/S0140-6736(88)90932-4] [PMID: 2904571]
[172]
Edwards, L.L.; Quigley, E.M.M.; Harned, R.K.; Hofman, R.; Pfeiffer, R.F. Defecatory function in Parkinson’s disease: Response to apomorphine. Ann. Neurol., 1993, 33(5), 490-493.
[http://dx.doi.org/10.1002/ana.410330512] [PMID: 8498826]
[173]
Tison, F.; Wiart, L.; Guatterie, M.; Fouillet, N.; Lozano, V.; Henry, P.; Barat, M. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov. Disord., 1996, 11(6), 729-732.
[http://dx.doi.org/10.1002/mds.870110622] [PMID: 8914103]
[174]
Laffleur, F.; Wagner, J.; Barthelmes, J. A potential tailor-made hyaluronic acid buccal delivery system comprising rotigotine for Parkinson’s disease? Future Med. Chem., 2015, 7(10), 1225-1232.
[http://dx.doi.org/10.4155/fmc.15.66] [PMID: 26144261]
[175]
Bucolo, C.; Leggio, G.M.; Drago, F.; Salomone, S. Dopamine outside the brain: The eye, cardiovascular system and endocrine pancreas. Pharmacol. Ther., 2019, 203, 107392.
[http://dx.doi.org/10.1016/j.pharmthera.2019.07.003] [PMID: 31299315]
[176]
Kulshreshtha, D.; Ganguly, J.; Jog, M. Managing autonomic dysfunction in Parkinson’s disease: a review of emerging drugs. Expert Opin. Emerg. Drugs, 2020, 25(1), 37-47.
[http://dx.doi.org/10.1080/14728214.2020.1729120] [PMID: 32067502]
[177]
Quarracino, C.; Otero-Losada, M.; Capani, F.; Pérez-Lloret, S. State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson’s disease. Expert Opin. Pharmacother., 2020, 21(4), 445-457.
[http://dx.doi.org/10.1080/14656566.2020.1713097] [PMID: 31957505]
[178]
Schoffer, K.L.; Henderson, R.D.; O’Maley, K.; O’Sullivan, J.D. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov. Disord., 2007, 22(11), 1543-1549.
[http://dx.doi.org/10.1002/mds.21428] [PMID: 17557339]
[179]
Elshoff, J.P.; Bauer, L.; Goldammer, N.; Oortgiesen, M.; Pesch, H.; Timmermann, L. Randomized, double-blind, crossover study of the adhesiveness of two formulations of rotigotine transdermal patch in patients with Parkinson’s disease. Curr. Med. Res. Opin., 2018, 34(7), 1293-1299.
[http://dx.doi.org/10.1080/03007995.2018.1430559] [PMID: 29461870]
[180]
Jenner, P.; Könen-Bergmann, M.; Schepers, C.; Haertter, S. Pharmacokinetics of a Once-Daily extended-release formulation of pramipexole in healthy male volunteers: Three studies. Clin. Ther., 2009, 31(11), 2698-2711.
[http://dx.doi.org/10.1016/j.clinthera.2009.10.018] [PMID: 20110012]
[181]
Perez-Lloret, S.; Rey, M.V.; Crispo, J.; Krewski, D.; Lapeyre-Mestre, M.; Montastruc, J.L.; Rascol, O. Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients. Expert Opin. Drug Saf., 2014, 13(3), 351-360.
[http://dx.doi.org/10.1517/14740338.2014.888057] [PMID: 24547918]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy